Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  ProMIS Neurosciences, Inc.    PMN   CA74346M1095


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

ProMIS Neurosciences : Completes Second Closing of Private Placement

share with twitter share with LinkedIn share with facebook
share via e-mail
01/02/2020 | 09:28am EDT

TORONTO - ProMIS Neurosciences, Inc. ('ProMIS' or the 'Company') (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases is pleased to announce that further to its news releases dated November 13, 2019 and November 18, 2019, it completed, on December 31, 2019 the second closing of its private placement.

In the second closing, the Company issued 3,724,998 units (each a 'Unit') for gross proceeds of approximately CDN$745,000. The total gross proceeds raised to date under the private placement are $2,800,333.

In connection with the two closings insiders of the Company have subscribed for a total of 633,332 Units under the private placement representing approximately $126,666 of the private placement.

Each Unit issued in the second closing consisted of one common share of the Company (each a 'Share') and one share purchase warrant of the Company (each a 'Warrant'). Each Warrant entitles the holder thereof to purchase one Share ('a 'Warrant Share') at an exercise price of $0.35 per Warrant Share at any time for five years from the date of issuance.

All securities issued in the second closing will be subject to a four-month statutory hold period in accordance with applicable securities laws. Net proceeds from the second closing are intended to be used for working capital and general corporate purposes. Closing is subject to TSX approval.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information, including about the timing and completion of the Offering, the receipt of TSX approval and the expected use of proceeds from the Offering. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Shanti Skiffington

Tel: 617 921-0808

Email: shanti.skiffington@gmail.com

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
05/28ProMIS Neurosciences and collaborative team receive Supercluster Award suppor..
05/21PROMIS NEUROSCIENCES : Chairman's Update details new programs from expanded use ..
05/20PROMIS NEUROSCIENCES : and BC Neuroimmunology expand collaboration to develop an..
05/20PROMIS NEUROSCIENCES : Chairman's Memorandum, May 20, 2020
05/20ProMIS Neurosciences Chairman's Update details new programs from expanded use..
05/19ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop a..
05/13ProMIS Neurosciences Announces First Quarter 2020 Results
05/12ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for deve..
05/06ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved..
04/30ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dement..
More news
Sales 2020 - - -
Net income 2020 -6,90 M -5,09 M -5,09 M
Net Debt 2020 - - -
P/E ratio 2020 -10,2x
Yield 2020 -
Capitalization 54,9 M 40,3 M 40,5 M
EV / Sales 2019
Capi. / Sales 2020 -
Nbr of Employees -
Free-Float 88,4%
Duration : Period :
ProMIS Neurosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 2
Average target price 2,34 $
Last Close Price 0,14 $
Spread / Highest target 2 661%
Spread / Average Target 1 528%
Spread / Lowest Target 396%
EPS Revisions
Elliot Goldstein President, Chief Executive Officer & Director
Eugene Williams Executive Chairman
Daniel E. Geffken Chief Financial Officer
Neil R. Cashman Director & Chief Scientific Officer
James Kupiec Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.18.41%24 620
GENMAB A/S39.05%20 072